Phase 3 interim analysis: Tezacaftor/ivacaftor (TEZ/IVA) in patients heterozygous for F508del-cystic fibrosis transmembrane conductance regulator (CFTR) and residual function (RF) mutation

13:00 - 13:15

Speaker: Peter Middleton

Cytochrome interactions of cystic fibrosis modulators and resulting plasma concentrations

13:15 - 13:30

Speaker: Elena Schneider-Futschik

Extracellular traps as a therapeutic target in early-stage cystic fibrosis

13:30 - 13:45

Speaker: Jennifer Schafer

Rescue of CFTR function impaired by mutations in exon 15 in children with cystic fibrosis

13:45 - 14:00

Speaker: Kelly Martinovich

The cystic fibrosis gut microbiome: A major reservoir of transmissible antibiotic resistance

14:00 - 14:15

Speaker: Steven Taylor

Phase 3 interim analysis: Tezacaftor/ivacaftor (TEZ/IVA) in patients homozygous for F508del-cystic fibrosis transmembrane conductance regulator (CFTR)

14:15 - 14:30

Speaker: Daniel Smith